Request Demo
Last update 20 Mar 2025
Thymosin beta-4
Last update 20 Mar 2025
Overview
Basic Info
Drug Type Synthetic peptide |
Synonyms Fx peptide, Thymosin B4, Thymosin beta 4 + [15] |
Target |
Action modulators |
Mechanism thymosin beta 4 modulators(Thymosin Beta-4 modulators) |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization |
Drug Highest PhasePhase 3 |
First Approval Date- |
RegulationSpecial Review Project (China), Orphan Drug (United States) |
Login to view timeline
Structure/Sequence
Sequence Code 8196
Source: *****
Related
16
Clinical Trials associated with Thymosin beta-4CTIS2022-502697-16-00
SEER-3: A Phase 3, Multi-Center, Randomized, Parallel, Double Masked, Placebo-Controlled Clinical Study to Assess the Safety and Efficacy of 0.1% RGN-259 Ophthalmic Solution for the Treatment of Neurotrophic Keratopathy - SEER-3
NCT05555589
A Phase 3, Multi-Center, Randomized, Parallel, Double Masked, Placebo-Controlled Clinical Study to Assess the Safety and Efficacy of 0.1% RGN-259 Ophthalmic Solution for the Treatment of Neurotrophic Keratopathy (SEER-2)
NCT01311518
A Randomized, Double-blind, Placebo-Controlled, Study of the Safety and Efficacy of RGN-352 in Subjects With an Acute ST Elevation Myocardial Infarction (STEMI) After Occlusion of the Proximal Left Anterior Descending Coronary Artery
100 Clinical Results associated with Thymosin beta-4
Login to view more data
100 Translational Medicine associated with Thymosin beta-4
Login to view more data
100 Patents (Medical) associated with Thymosin beta-4
Login to view more data
429
Literatures (Medical) associated with Thymosin beta-401 Feb 2025Free Radical Biology and Medicine
Enhancing fat graft survival: thymosin beta-4 facilitates mitochondrial transfer from ADSCs via tunneling nanotubes by upregulating the Rac/F-actin pathway
Article
Author: Wang, Qian ; Lin, Yan ; Mu, Dali ; Zhang, Xiaoyu ; Li, Haoran
01 Nov 2024Asian Journal of Surgery
Therapeutic potential of thymosin beta 4 in a variety of diseases
Letter
Author: Dai, Qingmei ; Ye, Chaoqun ; Deng, Luyao ; Huang, Huizhi
01 Jun 2024Aesthetic Plastic Surgery
In Vitro Study of Thymosin Beta 4 Promoting Transplanted Fat Survival by Regulating Adipose-Derived Stem Cells
Article
Author: Mu, Dali ; Lin, Yan ; Yang, Yan ; Li, Wandi
16
News (Medical) associated with Thymosin beta-424 Aug 2023
Phase 3Drug ApprovalClinical Result
09 Jun 2023
Clinical ResultDrug Approval
07 Jun 2023
Drug ApprovalPhase 2Phase 3Accelerated Approval
100 Deals associated with Thymosin beta-4
Login to view more data
External Link
| KEGG | Wiki | ATC | Drug Bank |
|---|---|---|---|
| - | Thymosin beta-4 | - |
R&D Status
10 top R&D records. to view more data
Login
| Indication | Highest Phase | Country/Location | Organization | Date |
|---|---|---|---|---|
| Neurotrophic keratitis | Phase 3 | United States | 17 Sep 2015 | |
| Epidermolysis Bullosa Dystrophica | Preclinical | United States | 22 May 2019 | |
| Epidermolysis Bullosa Dystrophica | Preclinical | United States | 22 May 2019 | |
| Dry Eye Syndromes | Preclinical | United States | 01 Nov 2016 | |
| Diabetes Mellitus | Preclinical | United States | 01 Dec 2007 | |
| Varicose Ulcer | Preclinical | Italy | 01 Jul 2006 | |
| Varicose Ulcer | Preclinical | Poland | 01 Jul 2006 | |
| Pressure Ulcer | Preclinical | United States | 01 May 2006 | |
| Epidermolysis Bullosa | Preclinical | - | 01 Feb 2006 | |
| Wounds and Injuries | Preclinical | - | 01 Feb 2006 |
Login to view more data
Clinical Result
Clinical Result
Indication
Phase
Evaluation
View All Results
Phase 3 | 18 | (RGN-259) | uthalmbkil(owduberxws) = kwalltksxo giesnitesk (zxsjwuunrw, pjkuhpovbk - fbztfkakaa) View more | - | 14 Aug 2023 | ||
Placebo (Placebo) | uthalmbkil(owduberxws) = efuovloelm giesnitesk (zxsjwuunrw, aibsmecvfy - iukeulezyq) View more | ||||||
Phase 3 | 601 | (RGN-259) | cpsltzapeb(xeolmjtorg) = vclgaejbcg ppertlzwlc (mjikffkxbx, eoiikjkdvb - fqlzjxmqyx) View more | - | 05 Jan 2022 | ||
Placebo (Placebo) | cpsltzapeb(xeolmjtorg) = gzjuyzhnwh ppertlzwlc (mjikffkxbx, bizwsaxvlj - nehnpfzoyr) View more | ||||||
Phase 3 | Neurotrophic keratitis First line | 18 | (nupmwbchcj) = srqndbfhwx opcukovnxw (shfjrchuah ) | Positive | 13 Nov 2021 | ||
Placebo | (nupmwbchcj) = xmszasofcb opcukovnxw (shfjrchuah ) | ||||||
Phase 3 | 18 | yuodptcmys(qjdedxfudm) = xwwdvbhcej ycfzwrextg (titvqgofnu ) | Positive | 14 May 2020 | |||
Placebo | yuodptcmys(qjdedxfudm) = hmejftjypg ycfzwrextg (titvqgofnu ) | ||||||
Phase 3 | - | (uykszyckcj) = RGN-259 showed superiority over placebo in reducing corneal fluorescein staining in the change from baseline at days 15 and 29 (p=0.0207 and 0.0254, respectively). oldtsmxxlu (bufnkotjnq ) View more | Positive | 31 Oct 2017 | |||
Placebo | |||||||
NCT01387347 (Pubmed) Manual  | Phase 2 | 72 | utkatwxahw(yrhretzgwz) = bezlvmavma ycsqxpkwon (qhnaaenpht ) | Positive | 20 May 2015 | ||
Placebo | - | ||||||
Phase 2 | 30 | Thymosin Beta 4+placebo (Placebo) | (xniburcisr) = lylwfupvxk fnxgbgfoxt (lykasaqkkh, fugwoonnrh - fovsrrlkzi) View more | - | 10 Jun 2013 | ||
(Thymosin Beta 4) | (xniburcisr) = vcfqaztaig fnxgbgfoxt (lykasaqkkh, odcxrgyvmy - ntgsbazoly) View more | ||||||
Phase 2 | 72 | (Thymosin Beta 4) | kjnansfidn(lmqwjycnet) = pcakaofgkd dsvmoiccfk (gwbqxuhrkq, cawzlfwnrn - zvamuidmjy) View more | - | 24 Dec 2012 | ||
Placebo (Placebo) | kjnansfidn(lmqwjycnet) = mxykhxnhsb dsvmoiccfk (gwbqxuhrkq, sslogdvxtw - joelmrtrtt) View more |
Login to view more data
Translational Medicine
Boost your research with our translational medicine data.
login
or
Deal
Boost your decision using our deal data.
login
or
Core Patent
Boost your research with our Core Patent data.
login
or
Clinical Trial
Identify the latest clinical trials across global registries.
login
or
Approval
Accelerate your research with the latest regulatory approval information.
login
or
Biosimilar
Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.
login
or
Regulation
Understand key drug designations in just a few clicks with Synapse.
login
or
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free